Royalty Report: Medical, Supply, cardiac – Collection: 27295


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 5


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5

Primary Industries

  • Medical
  • Supply
  • cardiac
  • Surgical

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 27295

License Grant
The Company entered into an agreement with an undisclosed Licensor for a small diameter graft for vascular surgery.

IPSCIO Record ID: 27346

License Grant
Biograft peripheral vascular graft; Biograft is used to bypass occluded blood vessels and is produced from modified human umbilical veins; for use in lower limb vascular reconstructions when a saphenous vein is not available.

IPSCIO Record ID: 294016

License Grant
The University grants an exclusive, license, including the right to grant sublicenses, under the Patent Rights, to make, have made, sell, offer for sale, have sold, use, import, and have imported Licensed Products in the Field.
License Property
The patents are for Non-Human Mammal Having a Graft and Methods of Delivering Protein to Myocardial Tissue; and. Myocardial Grafts and Cellular Composition.
Field of Use
Licensee develops and manufacture fully functioning human cells in industrial quantities to precise specifications. Licensee's proprietary iCell Operating System (iCell O/S) includes true human cells in multiple cell types (iCell products), human induced pluripotent stem cells (iPSCs) and custom iPSCs and iCell products (MyCell products). iCell O/S products provide standardized, easy-to-use, cost-effective access to the human cell, the smallest fully functioning operating unit of human biology. Customers use iCell O/S products, among other purposes, for drug discovery and screening; to test the safety and efficacy of their small molecule and biologic drug candidates; for stem cell banking; and in researching cellular therapeutics.

IPSCIO Record ID: 2357

License Grant
Licensor and Licensee have  entered into agreement relating to certain technology.
License Property
'Licensed Products' shall mean any product, good, or item within the Field, produced in whole or in part, using a part or all of the technology embodied in Licensed Patents, and made of, but not limited to, Fluorinated Hydrocarbons (including, but not limited to, PTFE, ePTFE, FEP, PFA, HFP and VF).

A. Soft Tissue Includes Gore patch products used in the following applications
i)  Reconstruction of hernias and soft tissue deficiencies, such as abdominal wall defects, diaphragmatic hernia, laparoscopic hernia, pelvic floor and lid reconstruction, ventral hernia, laparoscopic inguinal hernia, muscle flap reconstruction, vaginal prolapse, rectal prolapse, scrotal hernia, gastric banding and temporary facial bridging; and
ii)  Plastic and reconstructive surgery, such as malarplasty, mentoplasty, rhinoplasty, maxilloplasty, frontal defects, reconstructive lip augmentations, orbital repair, facial folds, facial slings and auricuoplasty.

B. Cardiovascular Includes Gore patch products used in cardiovascular and cardiac patching, such as carotid patch, angioplasty, profundaplasty, AV access graft patching, septal defects, outflow tracts, aneurysm repair and other patch angioplasty.

C. Surgical Membrane/Adhesion Limiting Includes Gore patch products used in the following applications
i)   Reconstruction or repair of the peritoneum, where minimal adhesions to a prosthetic material are desired, such as infertility surgery, gynecological surgery and gynecological and surgical oncology;
ii)  Temporary or permanent prosthesis for the repair of dura mater during neurosurgery, such as tumor resection, tethered cord releases, trauma repair and Chiari decompression;
iii) Reconstruction of the pericardium where minimal adhesions are desired; and
iv)  Wrap for pedicled arterial conduits.

IPSCIO Record ID: 286596

License Grant
Licensor hereby grants to Licensee an exclusive, perpetual, sub-licensable license to Licensor’s Intellectual Property, Trade Marks (TM), and all technical knowhow in the Fields of Use including Coronary Artery Bypass Grafting, Peripheral Vascular Bypass grafting and other Vascular Surgeries, to enable it to file for regulatory approvals, CE certification, preclinical and clinical studies, manufacture, distribute, market and commercialize the product in the Territory.

Licensor grants to Licensee exclusive, perpetual, sub-licensable rights to Licensor’s IP, Trade Marks (TM), and all technical knowhow to manufacture, distribute, market and commercialize the product in all countries outside the Territory if in any country outside the Territory that Licensor grants to Licensee and Licensee pays for any or all patent related costs or files for registration or files for regulatory approvals, CE certification, preclinical and clinical studies.

Licensor hereby appoints Licensee as an exclusive Distributor of the Product for the Territory in the Field of Use. As such, Licensee shall have the authority to purchase, market and sell the Product in the Territory in the Field of Use. Licensee may not Actively Promote Sales (e.g. through promotion, advertising, or by establishing branches or distribution depots) outside of the Territory. Furthermore, Licensee may only Actively Promote Product for the Field of Use. Licensee hereby accepts such appointment and agrees to use its best efforts to maximize sales of the Product in the Territory in the Field of Use. Licensee acknowledges that Licensees right to distribute is for the Territory in the Field of Use only.

License Property
Products shall refer to the products listed below
DuraGraft – Vascular Conduit Solution- For use in Cardiac and Peripheral Bypass Grafting with Arteries and Veins and For Vascular Surgeries. The product DuraGraft is a two-component system. Licensor will produce product component A and B either as bulk product or in separate containers ready for packaging to Licensee. Licensor will assist Licensee at Licensee’s cost, with technology transfer to allow Licensee to complete the manufacturing of the DuraGraft product at its ISO13485 certified site in the Territory or and release the product for commercial use in Licensee territories.  Licensor will transfer all Intellectual Property and technologies to manufacture for the currently marketed liquid and the solid dosage form (powder formulation) that requires final development and scale up, of DuraGraft formulations to enable Licensee to manufacture the products at their manufacturing facilities for supply in the Territory.

A CE Marked Product – Notified Body is BSI, Netherlands

Trademarks shall refer to any trademark used by Licensor in connection with the Product, whether derived from common law use, from registration or from statutory protection against unfair competition, including without limitation those rights to Licensor’s corporate name, other trade names, model names and trademarks, including DURAGRAFT.

Intellectual Property and technologies are to manufacture for the currently marketed liquid and the solid dosage form (powder formulation) that requires final development and scale up, of DuraGraft formulations to enable Licensee to manufacture the products at their manufacturing facilities for supply in the Territory.

Field of Use
Field of Use shall refer to use of the Product to preserve vascular conduits used in bypasses in cardiovascular surgery, peripheral bypass surgery and other vascular surgeries.

DuraGraft is a vascular graft treatment that improves clinical outcomes by reducing the incidence and complications of graft failure.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.